Ticagrelor, the generic version of BRILINTA, developed by AstraZeneca and approved by USFDA in 2011. It inhibits platelet aggregation by antagonizing the P2Y12 receptor. It is indicated to reduce the rate of cardiovascular death, Myocardial Infarction, and Stroke in patients with Acute Coronary Syndrome (ACS) or a history of Myocardial Infarction (MI), it also reduces the risk of Stent Thrombosis. As per studies, Ticagrelor exhibited a more favorable efficacy vs. safety profile over the other drugs.

(1S, 2S, 3R, 5S)-3-[7-[[(1R, 2S)-2-(3, 4-difluorophenyl) cyclopropyl] amino]-5-propylsulfanyltriazolo [4, 5-d] pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1, 2-diol
Click here to download PDF document for more details.